GlassScriptPhysician profile
David Shiba
NPI 1255389300
$4,599.82
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,183 · 2020: $738 · 2021: $1,478 · 2022: $201.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $473.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $447.69 | 2019-2021 | |
| Seagen INC. | $375.74 | 2019-2021 | |
| Genentech USA, INC. | $343.35 | 2019 | |
| Lilly USA, LLC | $299.41 | 2020-2021 | |
| Amgen INC. | $294.68 | 2019-2020 | |
| Pfizer INC. | $276.53 | 2019-2022 | |
| Astellas Pharma US INC | $224.99 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $215.50 | 2019-2021 | |
| Eisai INC. | $213.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $197.56 | 2019 | |
| Incyte Corporation | $125.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.08 | 2019 | |
| Stemline Therapeutics INC. | $105.82 | 2019 | |
| Tesaro, INC. | $104.63 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $102.85 | 2019 | |
| Epizyme, INC. | $99.95 | 2021 | |
| Adc Therapeutics America, INC. | $99.59 | 2021 | |
| Gilead Sciences, INC. | $99.57 | 2021 | |
| Celgene Corporation | $94.51 | 2019 | |
| Foundation Medicine, INC. | $91.27 | 2020 | |
| Merck Sharp & Dohme LLC | $74.43 | 2019 | |
| Puma Biotechnology, INC. | $59.68 | 2020 | |
| Acrotech Biopharma INC. | $51.80 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $17.81 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shiba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.